title: Serum CA 125, CA 15.3 and CA 19.9 levels and surgical findings in patients undergoing second look operations for ovarian carcinomas.
abstract: Sera from 52 ovarian cancer patients undergoing chemotherapy and second look operation were studied. CA 125, CA 15.3 and CA 19.9 assays were performed during chemotherapy and prior to relaparotomy. Twenty-six patients (50%) had no evidence of disease whereas 2 (3.8%) and 24 (46.1%) had microscopic and macroscopic disease. In general although the predictive value of an elevated CA 125 or CA 15.3 level is excellent, a normal value (less than 35 U/ml) has limited significance. Moreover, we found no improvement in negative predictive and positive predictive value by adding the determination of CA 19.9.
authors.affiliation: Gynecologic Oncology Department, Hospital de Cruces, Bilbao, Spain.
authors.forename: G
authors.initials: G
authors.lastname: Barrenetxea
authors.forename: M
authors.initials: M
authors.lastname: Martin-Mateos
authors.forename: M J
authors.initials: MJ
authors.lastname: Barzazan
authors.forename: F
authors.initials: F
authors.lastname: Montoya
authors.forename: J C
authors.initials: JC
authors.lastname: Matia
authors.forename: F J
authors.initials: FJ
authors.lastname: Rodriguez-Escudero
mesh_terms: D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000032:analysis*; D005260:Female; D006801:Humans; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000601:surgery; D011379:Prognosis; D011863:Radioimmunoassay
chemical_list: D000911:Antibodies, Monoclonal; D015295:Antigens, Tumor-Associated, Carbohydrate